Abstract: The present invention relates to a chromatographic device for isolating and purifying nucleic acids, preferably genomic DNA, by gel filtration chromatography, a method for isolating and purifying nucleic acids, preferably genomic DNA, using this device and a kit comprising this device.

Abstract: Minor groove binder phosphoramidites having unique structures have been synthesized according to particular methods. These minor groove binder phosphoramidites are useful in the preparation of oligonucleotide conjugates, particularly those for use as probes and primers.

Abstract: A method for producing digestion-resistant dextrin from starch hydrolyzates is disclosed. In one form, the method includes mixing the starch hydrolyzate, dextrose and an acid catalyst which are allowed to react under mild vacuum with heat. The ingredients require no pre-drying and the method requires no external plasticizers.

Abstract: The invention concerns a device for synthesis of radiopharmaceutical products based on chemical reagents contained in bottles, said device comprising several reaction compartments, transfer means between said bottles and said reaction compartments as well as mechanical means acting on said transfer means and enabling to monitor and control mechanically the transfer of chemical reagents. The invention is characterized in that it comprises: a fixed module including at least the mechanical means; a removable and disposable module, essentially in the shape of a support, whereon are arranged the transfer means between said bottles and said reaction compartments, said removable and disposable module not including any mechanical means; and means for securing said removable and disposable module to said fixed module.

Abstract: A process is described, comprising the oxidation of 17?-(3-hydroxypropyl)-6?,7?,15?,16?-dimethylen-5?-androstan-3?,5,17?-triol, for the preparation of drospirenone, a synthetic steroid with progestogenic, antimineralocorticoid and antiandrogenic activity, useful for preparing pharmaceutical compositions with contraceptive action.

Abstract: The cobalt(II) complex of new D2-symmetric chiral porphyrin 3,5-DiMes-ChenPhyrin, [Co(P2)], has been shown to be a highly effective chiral metalloradical catalyst for enantioselective cyclopropenation of alkynes with acceptor/acceptor-substituted diazo reagents such as ?-cyanodiazoacetamides and ?-cyanodiazoacetates. The [Co(P2)]-mediated metalloradical cyclopropenation is suitable to a wide range of terminal aromatic and related conjugated alkynes with varied steric and electronic properties, providing the corresponding tri-substituted cyclopropenes in high yields with excellent enantiocontrol of the all-carbon quaternary stereogenic centers. In addition to mild reaction conditions, the Co(II)-based metalloradical catalysis for cyclopropenation features a high degree of functional group tolerance.

Abstract: The invention relates to heteroaryl aryl ureas of the formula IA, wherein the radicals and symbols have the meanings as defined herein, the use of such compounds in the treatment of protein kinase dependent diseases; to pharmaceutical preparations comprising said heteroaryl aryl ureas, to processes for the manufacture of such novel compounds and to methods of treatment comprising the use of such heteroaryl aryl ureas.

Abstract: Methods of preparing compounds of formula i(1): or a pharmaceutically acceptable salt thereof, wherein: R1 and R2 join together with the nitrogen atom to which they are attached to form a 6 membered heterocycloalkyl group; X1 is H, Br, Cl or F; X2 is H, Br, Cl or F; s is 2-6; n1 is 0-2; and n2 is 0-2.

Abstract: The invention relates to small molecules which function as inhibitors of the interaction between p53 and MDM2. The invention also relates to the use of these compounds for inhibiting cell growth, inducing cell death, inducing cell cycle arrest and/or sensitizing cells to additional agent(s).

Abstract: Disclosed is a composition effective in reducing skin wrinkles. The composition comprises or uses a phosphodiesterase 5 (PDE5) inhibitor as an active ingredient. Further disclosed is a method for reducing skin wrinkles using the composition.

Abstract: The present invention provides metal-porphyrin carbon nanostructures, which have excellent oxygen reduction performance and are useful as materials for fuel cell electrodes.

Abstract: Provided herein are improved, commercially viable and industrially advantageous processes for the preparation of a substantially pure ticagrelor intermediate, 4,6-dichloro-5-nitro-2-(propylthio)pyrimidine, Formula (II). The intermediate is useful for preparing ticagrelor, or a pharmaceutically acceptable salt thereof in high yield and purity.

Abstract: Synthesis process of dasatinib is disclosed, which includes the step of reacting the compound of formula I with that of formula II to obtain the compound of formula III. Also disclosed is the compound of formula III which is used as an intermediate for synthesizing dasatinib. The substituents of R1, R2, R3 or R4 in formulae I, II or III are defined as in the description.

Abstract: A method for making the compound of Formula I: is set forth using alkylation, amidation, chlorination and phosphate installation procedures.

Abstract: It is disclosed a process for the preparation of a compound of formula (I) or a salt thereof, comprising: nitrating a compound of formula (II) or a salt thereof, to obtain a compound of formula (IV) or a salt thereof, reducing it, to obtain a compound of formula (V) or a salt thereof, and subsequently cyclizing it to obtain a compound of formula (I) or a salt thereof and, if desired, converting a compound of formula (I) to a salt thereof, or vice versa, characterized in that: the nitration of a compound of formula (II) or a salt thereof is carried out with concentrated nitric acid in the presence of a strong inorganic acid and that the amino group in the compound of formula (II) is not protected.

Abstract: Disclosed are compounds and methods for treating neurological and other disorders by administering to a subject in need thereof an effective amount of a compound having binding and/or modulation specificity for GFR? receptor molecules, which can be mimetics of glial-derived neurotrophic factor (GDNF) family ligands (GFLs), GFR?/RET signaling pathway agonists, and/or direct RET agonists (activators).

Abstract: The invention provides a compound of Formula (I) or a pharmaceutically acceptable salt of the compound, wherein R1, R2, R3 and R4 are as described herein; pharmaceutical compositions thereof; and the use thereof in treating diseases, conditions or disorders modulated by the inhibition of an acetyl-CoA carboxylase enzyme(s) in an animal.

Abstract: Present invention relates to methods for preparing (1?, 2?, 4?, 5?, 7?)-7-[(hydroxidi-2-thienllacetyl)oxy]-9,9-dimethyl-3-oxa-9-azoniatricyclo[3.3.1.02,4]nonane-bromide.

Abstract: The object of the present invention is a one-pot process for preparing the 2-acetoxy-5-(2-fluoro-?-cyclopropyl-carbonyl-benzyl)-4,5,6,7-tetrahydro-4H-tieno[3,2-c]-pyridine (prasugrel) of the formula (I) by reacting the 5,6,7,7a-tetrahydro-4H-tieno[3,2-c]-pyridine-2-on of the formula (II) with 2-bromo-1-cyclopropyl-2-(2-fluorophenyl)-etanone of the formula (III) or with 2-chloro-1-cyclopropyl-2-(2-fluorphenyl)-etanone of the formula (IIIa) and acetylating of the formed compound of the formula (IV), wherein the reaction is carried out in the presence of an organic base with an acetylation agent without isolating the compound of the formula (IV). The coupling and acetylation are carried out in the presence of the same organic base such as triethylamine, N,N-diisopropyl-ethylamine or pyridine. At the end of the process the prasugrel of the formula (I) is purified by recrystallization from an organic solvent or a mixture of solvents.

Abstract: A radioisotope labeled reagent includes a compound having the general formula (I), L-(aCbH2)naCbH3??(I) where a in each occurrence independently is a carbon mass number between 11 and 14 inclusive, b in each occurrence independently is a hydrogen mass number between 1 and 3 inclusive, such that a in each occurrence is not 12 simultaneously with b in each occurrence being 1; L is a leaving group R1SO2—O—, R1—S—, 12C1H3(12C3H2)n—S—R1C(O)O—, NC—, (R1)3P—, XMg—and Li—, where n is an integer between 0 and 3 inclusive, where X is chloro, bromo or iodine, where R1 is H, aryl, a substituent containing aryl, C1-C20 alkyl, a substituent containing C1-C20 alkyl, C2-C20 alkenyl, a substitute containing C2-C20 alkenyl, C2-C20 alkynyl, and a substitute containing C2-C20 alkynyl with the proviso that when n is 0, a is 13 and b is 2 and R1 in R1—S is not aryl.

Abstract: The invention provides a crystalline hydrochloride salt of 4-[2-(2,4,6-trifluorophenoxymethyl)phenyl]piperidine. This invention also provides pharmaceutical compositions comprising the crystalline salt, processes and intermediates for preparing the crystalline salt, and methods of using the crystalline salt to treat diseases.

Abstract: A process for the enantioselective synthesis of a sulphoxide of a compound of Formula I or a pharmaceutically acceptable salt thereof in the form of a single enantiomer or in an enantiomerically enriched form wherein R1 to R4 are same or different and selected from the group consisting of hydrogen, C1 to C4 linear or branched alkyl, C1 to C4 linear or branched alkoxy, aryl, aryloxy alkoxy substituted by halogen or alkoxyalkoxy; X is either CH or N, said process comprising oxidizing the prochiral sulphide, compound of Formula II in an organic solvent with an oxidizing agent in presence of titanium (IV)alkoxide, (?)-Diethyl-D-tartrate, C1-C4 alcohol, and water; and optionally converting the compound of formula I into a pharmaceutically acceptable salt.

Abstract: A process for (R,S)-nicotine is described. Condensation of 1-(but-1-enyl) pyrrolidin-2-one with nicotinic acid ester gave 1-(but-1-enyl)-3-nicotinoylpynolidin-2-one which on treatment with an acid and a base gave myosmine. Myosmine was converted to (R,S)-nicotine by reduction followed by N-methylation.

Abstract: A process for (R,S)-nicotine is described. Condensation of 1-(but-1-enyl) pyrrolidin-2-one with nicotinic acid ester gave 1-(but-1-enyl)-3-nicotinoylpyrrolidin-2-one which on treatment with an acid and a base gave myosmine. Myosmine was converted to (R,S)-nicotine by reduction followed by N-methylation.

Abstract: Compounds having the formula are useful for inhibiting protein tyrosine kinases. The present invention also discloses methods of making the compounds, compositions containing the compounds, and methods of treatment using the compounds.

Abstract: The present disclosure relates to a process for trifluoromethylsulfinyl pyrazole compound of formula I, from a compound of formula III, wherein, R, R1 and R2 represent a group containing halogen group respectively and R3 represents a perhaloalkyl.

Abstract: Metal-containing complexes with general formula (1) (R1nPyr)(R2nPyr)ML1L2; or (2) [(R8XR9)(R1nPyr)(R2nPyr)]ML1L2 are disclosed; wherein M is a Group IV metal, Pyr is pyrrolyl ligand, n=1, 2 and 3, L1 and L2 are independently selected from alkoxide, amide or alkyl, L1 and L2 can be linked together, R1 and R2 can be same or different organic groups substituted at 2,3,4-positions of the pyrrole ring and are selected from the group consisting of linear and branched C1-6 alkyls, Wand R9 are independently selected from the linear or branched chain alkylene group having 2-6 carbon atoms, and X is CH2 or oxygen. Methods of using the metal complexes as precursors to deposit metal or metal oxide films used for various devices in semi-conductor industries are also discussed.

Abstract: The inventors disclose here a novel, facile approach to the synthesis of acetonide-protected catechol-containing compounds having at least one amine group. In specific embodiments, the invention provides novel methods of synthesizing 3,4-dihydroxyphenylalanine (H-DOPA(acetonide)-OH (6)), Fmoc-protected H-DOPA(acetonide)-OH (Fmoc-DOPA(acetonide)-OH (7)), Fmoc-protected dopamine (Fmoc-dopamine(acetonide) (10)), TFA-protected dopamine (TFA-dopamine(acetonide) (13)) and acetonide-protected 4-(2-aminoethyl)benzene-1,2-diol (acetonide-protected dopamine (14)).

Abstract: The present invention relates to a method comprising (A) reacting a ?-keto ester with a 2-halo ester under basic conditions to obtain a 2-aceto-3-methyl-succinic acid ester; (B) reacting the resulting 2-aceto-3-methyl-succinic acid ester with methyl vinyl ketone under basic conditions, optionally followed by a decarboxylation reaction and hydrolysis, etc., to obtain an ?-methyl-?-keto acid; and (C) reducing the resulting ?-methyl-?-keto acid to obtain wine lactone or a stereoisomer thereof or a mixture thereof.

Abstract: The present invention relates to a metal catalyst composition for producing furfural derivatives from raw materials of lignocellulosic biomass, and method for producing furfural derivatives using the composition. The present invention comprises ruthenium chloride (RuCl3) and chromium chloride (CrCl2). The chromium chloride (CrCl2) is from 300 to 500 parts by weight on the basis of 100 parts by weight of the ruthenium chloride (RuCl3). Unlike conventional furfural derivatives producing process that should go through multi step processes such as pre-process, saccharification process, etc, the present invention has an advantage of producing furfural derivatives from lignocellulosic raw material only through simple reaction process in one reaction apparatus by mixing various kinds of metal catalyst at an optimum ratio.

Abstract: The invention provides crystalline minocycline base. In particular, three crystalline polymorphic forms, designated Form I, Form II and Form III, of minocycline base are provided. These are characterised by XRD and IR data. Processes for preparing the new polymorphic forms are also provided. For example, Form I is prepared by dissolving and/or suspending amorphous minocycline base in an organic solvent chosen from ethers followed by crystallisation from the mixture.

Abstract: A process for extracting seed-oil from an oil-containing seed product comprises (a) providing the seed product to a grinder; (b) providing a first liquid comprising a solvent to the grinder; (c) grinding the seed product and the first liquid to yield a slurry; (d) subjecting the slurry to a slurry extraction and slurry separation step to yield a processed seed product and a liquid product comprising seed-oil and solvent; and (e) subjecting the liquid product to an oil separation step to at least partially separate the seed-oil from the solvent.

Abstract: A surfactant concentrate is provided that includes C8-C22 acyl amido compounds, a polyol and C8-C22 fatty acids. The concentrate is formed via an interesterification reaction between a C1-C3 alkyl ester of a C8-C22 fatty acid and an amino compound or salt thereof in a polyol. The resultant surfactant concentrate will have a Hunter Lab Color Scale value L ranging from 70 to 100.

Abstract: A process is provided for preparing C8-C22 acyl amido compounds via reaction in a polyol (molecular weight 76 to 400) of interesterifying a fatty acid ester with an amino compound or salt thereof. The resultant mass of material will have a Hunter Lab Color Scale value L ranging from 70 to 100.

Abstract: A reagent composition for forming fatty acyl amido surfactants is provided which includes an alkali metal or alkaline earth metal salt of an amino compound; a polyol of molecular weight ranging from 76 to 300; and no more than 10% water.

Abstract: A surfactant concentrate is provided that includes C8-C22 acyl amido compounds, a polyol and C8-C22 fatty acids. The concentrate is formed via an interesterification reaction between a fatty acid ester and an amino compound or salt thereof in a polyol. The resultant surfactant concentrate will have a Hunter Lab Color Scale value L ranging from 70 to 100.

Abstract: A process is provided for preparing C8-C22 acyl glycinate acid or salt thereof via reacting and heating a mixture of glycine or salt thereof with a C1-C3 alkyl ester of a C8-C22 fatty acid in a medium of glycerol or propylene glycol. The reaction proceeds well where the mixture is formulated to have a pKa ranging from 9.5 to 13.

Abstract: A process is provided for preparing C8-C22 acyl glycinate acid or salt thereof via reacting and heating reacting a mixture of glycine or salt thereof with a fatty acid ester in a medium selected from the group consisting of glycerol, propylene glycol and combinations thereof, and wherein the mixture has a pKa ranging from 9.5 to 13.

Abstract: A process is provided for preparing C8-C22 acyl amido compounds via reaction in a polyol (molecular weight 76 to 400) of interesterifying a C1-C3 alkyl ester of a C5-C22 fatty acid with an amino compound or salt thereof. The resultant mass of material will have a Hunter Lab Color Scale value L ranging from 70 to 100.

Abstract: A method for the manufacture of aminopolyalkylene phosphonic acid of a specific general formula is described. In particular, a mixture of specifically defined ranges of reactants to wit: phosphorous acid; an amine; formaldehyde and an aminopolyalkylene phosphonic acid, having the same general formula as the compound to be manufactured, are reacted to thus yield a product of outstanding selectivity and purity with substantially reduced levels of non-desirable by-products.

Abstract: A method of esterifying free fatty acid in natural oil comprises heating the natural oil (2) to a first temperature above a reaction temperature, feeding the heated natural oil into an acid-resistant pipe reactor (5), providing a mixture of acid catalyst (6) and short chain alcohol (8) at a second temperature below the reaction temperature, and feeding the mixture of acid catalyst and short chain alcohol into the natural oil in the pipe reactor (5). The short chain alcohol and free fatty acid react at the reaction temperature to form an ester.

Abstract: A superparamagnetic nanoparticle is comprised of superparamagnetic nanocrystals less than 20 nm in size, and molecules having containing 3 to 5 carboxyl groups, wherein the molecules bond to surfaces of the superparamagnetic nanocrystals. A method for producing superparamagnetic nanoparticles includes preparing an alkaline solution with pH 10 to 14, producing a mixture in which molecules containing 3 to 5 carboxyl groups, a divalent transition metal and ferric precursors are dissolved, and adding the mixture into the alkaline solution.

Abstract: This invention relates to the preparation of a partially quaternized ammonium organosilane composition, and a self-stabilizing aqueous solution of said composition, which serves to yield an antimicrobial polysilsesquioxane coating upon thermal curing. By way of this invention, an aqueous solution is prepared, comprised in part by a partially quaternized ammonium organosilane hydrolysate, characterized in that no further manipulation or addition of potentially costly ingredients are required to yield a stable and hence marketable product.

Abstract: A modified polysiloxane compound is represented by following Formula (1), in which R1 to R9 represent hydrocarbon groups selected from linear alkyl groups having 1 to 20 carbon atoms, branched chain alkyl groups having 3 to 6 carbon atoms, and cyclic alkyl groups having 3 to 6 carbon atoms; p and q represent average numbers of siloxane units indicated in parentheses, where p is a number of 1 or more and q is a number of 2 or more; and “A” represents a group selected from a group represented by following Formula (2), a group represented by following Formula (3), and hydrogen atom. The modified polysiloxane compound has at least a siloxane unit wherein “A” is the group represented by following Formula (2), and a siloxane unit wherein “A” is the group represented by following Formula (3).

Abstract: Provided herein are ruthenium complexes of Formula I, and processes of preparation thereof. Also provided are methods of their use as a metathesis catalyst.

Abstract: The invention provides novel compounds and methods to carry out organocatalytic Michael additions of aldehydes to nitroethylene catalyzed by a proline derivative to provide ?-substituted-?-nitroaldehydes. The reaction can be rendered enantioselective when a chiral pyrrolidine catalyst is used, allowing for Michael adducts in nearly optically pure form (e.g., 96-99% e.e.). The Michael adducts can bear a single substituent or dual substituents adjacent to the carbonyl. The Michael adducts can be efficiently converted to protected ?2-amino acids, which are essential for systematic conformational studies of ?-peptide foldamers.

Abstract: A bicyclohexane derivative compound useful in the field of photoresist, the field of intermediate of drugs and pesticides, and the like, and a manufacturing method of the same are provided. A bicyclohexane derivative compound represented by the following general formula (II) is provided. (In formula (II), Y independently represents an alkyl group of 1 to 10 carbons, a halogen atom, an acyloxy group, an alkoxycarbonyl group or a hydroxyl group, X1 represents a halogen atom, m represents an integer of 0 to 11, and m represents an integer of 0 to 10.

Abstract: Provided are an alicyclic structure-containing compound, a (meth)acrylate, and a method for producing the ester. The compound and the ester are useful as a monomer and the like for a photoresist used in semiconductor manufacturing and excellent in solubility, compatibility, defect reduction, roughness improvement, and the like, realized by using an alicyclic structure-containing compound containing a linking group having an ester bond and/or a linking group having an ether bond, a (meth)acrylate derived from the alicyclic structure-containing compound, and a method for producing the ester.

Abstract: Provided herein are methods of isolating a 4-chloro-2-fluoro-3-substituted-phenylboronic acid. The method comprises contacting a mixture of water, a water miscible organic solvent, and a 4-chloro-2-fluoro-3-substituted-phenylboronic acid with a salt to form a water miscible organic solvent layer and a water layer. The 4-chloro-2-fluoro-3-substituted-phenylboronic acid is partitioned into the water miscible organic solvent layer, which is separated from the water layer. Additional methods are disclosed, as is a 4-chloro-2-fluoro-3-substituted-phenylboronic acid produced by one of the methods, wherein the 4-chloro-2-fluoro-3-substituted-phenylboronic acid is obtained at a yield of greater than approximately 90%.

Abstract: The invention provides an improved process for the preparation of a benzonaphthalene derivative including, in particular, the manufacture of high purity adapalene. The invention further includes a method for assessing the color of adapalene by means of a quantitative colorimetric measurement of the produced adapalene.